Week In Review: VistaGen Out-Licenses China/Asia Rights For Novel Anxiety Drug To EverInsight In $177 Million Deal
Company News
- WuXi NextCODE will restructure its genomics services operations by separating from its Shanghai office (see story). The new company, known as Genuity Science, will consist of NextCODE's Boston office as headquarters, plus existing operations in Dublin and Reykjavik. The company cited China's Human Genetic Resource Regulation (HGRAC), which prohibits ex-China use of China genomic data, as the reason for the restructuring.
- AnchorDx, a Guangzhou diagnostics company, announced progress on its next-gen blood-based DNA cancer test that will screen for six types of cancer at a cost as low as $100 (see story). The test, named Aurora, uses the company's ctDNA methylation detection technology to test for lung, breast and digestive system cancers (colorectum, stomach, esophagus and liver), which together account for 65% of new cancer cases in China. AnchorDx said the one-tube DNA test offers high sensitivity and specificity, short turn-around time and low cost.
Disclosure: None
How did you like this article? Let us know so we can better customize your reading experience.
Comments
Leave a comment to automatically be entered into
our contest to win a free Echo Show.
